Best ways to prevent heart disease in breast, prostate, and lung cancer survivors
Modeling Best Approaches for Cardiovascular Disease Prevention in Cancer Survivors
It compares prevention options like statins and aspirin to help breast, prostate, and lung cancer survivors lower their risk of heart disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11296887 on NIH RePORTER |
What this research studies
From your perspective as a cancer survivor, researchers will use large patient databases and computer models to estimate heart disease risk after cancer and to see how prevention choices like cholesterol medicines or aspirin might change that risk. The work will account for cancer treatments, other health problems, and genetic risk factors so recommendations fit people with different histories. Models will also consider how cancer recurrence or limited life expectancy might change the long-term benefits of prevention. The goal is to identify which prevention strategies are likely to help specific groups of survivors.
Who could benefit from this research
Good fit: Adults who have completed treatment for breast, prostate, or lung cancer and who are worried about or have risk factors for heart disease (for example high cholesterol, high blood pressure, or prior cardiotoxic cancer therapy) would be the primary group this work aims to help.
Not a fit: People currently receiving active cancer therapy, those with very limited life expectancy, or those with no cardiovascular risk factors may be less likely to benefit from the prevention strategies prioritized by this work.
Why it matters
Potential benefit: If successful, this could help doctors pick heart disease prevention approaches that reduce cardiovascular deaths and improve quality of life for cancer survivors.
How similar studies have performed: Statins and aspirin have proven benefits for preventing heart disease in the general population, but applying and tailoring these strategies specifically to cancer survivors is relatively new.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Wisnivesky, Juan P — Icahn School of Medicine at Mount Sinai
- Study coordinator: Wisnivesky, Juan P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.